|
Gene: CDH11 |
Gene summary for CDH11 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CDH11 | Gene ID | 1009 |
Gene name | cadherin 11 | |
Gene Alias | CAD11 | |
Cytomap | 16q21 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P55287 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1009 | CDH11 | AEH-subject1 | Human | Endometrium | AEH | 4.24e-22 | -5.47e-01 | -0.3059 |
1009 | CDH11 | AEH-subject2 | Human | Endometrium | AEH | 1.20e-30 | -5.98e-01 | -0.2525 |
1009 | CDH11 | AEH-subject3 | Human | Endometrium | AEH | 9.60e-17 | -5.30e-01 | -0.2576 |
1009 | CDH11 | AEH-subject4 | Human | Endometrium | AEH | 2.59e-03 | -1.78e-01 | -0.2657 |
1009 | CDH11 | AEH-subject5 | Human | Endometrium | AEH | 1.05e-14 | -5.18e-01 | -0.2953 |
1009 | CDH11 | EEC-subject1 | Human | Endometrium | EEC | 1.06e-28 | -5.72e-01 | -0.2682 |
1009 | CDH11 | EEC-subject2 | Human | Endometrium | EEC | 1.02e-23 | -5.78e-01 | -0.2607 |
1009 | CDH11 | EEC-subject3 | Human | Endometrium | EEC | 1.15e-28 | -5.43e-01 | -0.2525 |
1009 | CDH11 | EEC-subject4 | Human | Endometrium | EEC | 4.40e-20 | -5.19e-01 | -0.2571 |
1009 | CDH11 | EEC-subject5 | Human | Endometrium | EEC | 9.95e-29 | -5.88e-01 | -0.249 |
1009 | CDH11 | GSM5276935 | Human | Endometrium | EEC | 2.48e-30 | -5.91e-01 | -0.123 |
1009 | CDH11 | GSM5276937 | Human | Endometrium | EEC | 3.17e-02 | -2.93e-01 | -0.0897 |
1009 | CDH11 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 9.29e-28 | -6.04e-01 | -0.1869 |
1009 | CDH11 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 8.81e-25 | -6.04e-01 | -0.1875 |
1009 | CDH11 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.03e-28 | -6.04e-01 | -0.1883 |
1009 | CDH11 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.01e-22 | -4.93e-01 | -0.1934 |
1009 | CDH11 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 4.04e-30 | -5.80e-01 | -0.1917 |
1009 | CDH11 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.85e-34 | -5.92e-01 | -0.1916 |
1009 | CDH11 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 5.17e-08 | -3.58e-01 | -0.1269 |
1009 | CDH11 | P2T-E | Human | Esophagus | ESCC | 1.02e-41 | 8.54e-01 | 0.1177 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00074098 | Endometrium | AEH | axonogenesis | 81/2100 | 418/18723 | 5.54e-07 | 2.12e-05 | 81 |
GO:00615648 | Endometrium | AEH | axon development | 88/2100 | 467/18723 | 6.39e-07 | 2.38e-05 | 88 |
GO:00015038 | Endometrium | AEH | ossification | 78/2100 | 408/18723 | 1.54e-06 | 4.85e-05 | 78 |
GO:00343299 | Endometrium | AEH | cell junction assembly | 78/2100 | 420/18723 | 4.80e-06 | 1.24e-04 | 78 |
GO:004521610 | Endometrium | AEH | cell-cell junction organization | 42/2100 | 200/18723 | 4.26e-05 | 7.20e-04 | 42 |
GO:000704310 | Endometrium | AEH | cell-cell junction assembly | 30/2100 | 146/18723 | 7.29e-04 | 6.98e-03 | 30 |
GO:00343327 | Endometrium | AEH | adherens junction organization | 12/2100 | 49/18723 | 6.75e-03 | 3.94e-02 | 12 |
GO:006156412 | Endometrium | EEC | axon development | 93/2168 | 467/18723 | 9.60e-08 | 4.69e-06 | 93 |
GO:000740912 | Endometrium | EEC | axonogenesis | 82/2168 | 418/18723 | 1.03e-06 | 3.49e-05 | 82 |
GO:000150313 | Endometrium | EEC | ossification | 79/2168 | 408/18723 | 2.72e-06 | 7.67e-05 | 79 |
GO:003432914 | Endometrium | EEC | cell junction assembly | 79/2168 | 420/18723 | 8.37e-06 | 1.85e-04 | 79 |
GO:004521615 | Endometrium | EEC | cell-cell junction organization | 42/2168 | 200/18723 | 8.84e-05 | 1.25e-03 | 42 |
GO:000704315 | Endometrium | EEC | cell-cell junction assembly | 31/2168 | 146/18723 | 5.74e-04 | 5.72e-03 | 31 |
GO:000150317 | Esophagus | ESCC | ossification | 232/8552 | 408/18723 | 3.00e-06 | 3.40e-05 | 232 |
GO:006156415 | Esophagus | ESCC | axon development | 251/8552 | 467/18723 | 2.41e-04 | 1.49e-03 | 251 |
GO:003432918 | Esophagus | ESCC | cell junction assembly | 227/8552 | 420/18723 | 3.06e-04 | 1.83e-03 | 227 |
GO:004521620 | Esophagus | ESCC | cell-cell junction organization | 114/8552 | 200/18723 | 8.04e-04 | 4.16e-03 | 114 |
GO:000740915 | Esophagus | ESCC | axonogenesis | 219/8552 | 418/18723 | 3.14e-03 | 1.31e-02 | 219 |
GO:000150310 | Oral cavity | OSCC | ossification | 203/7305 | 408/18723 | 5.54e-06 | 6.19e-05 | 203 |
GO:004521618 | Oral cavity | OSCC | cell-cell junction organization | 97/7305 | 200/18723 | 3.83e-03 | 1.57e-02 | 97 |
Page: 1 2 3 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
ANGPTL4 | CDH11 | ANGPTL4_CDH11 | ANGPTL | Breast | DCIS |
ANGPTL4 | CDH11 | ANGPTL4_CDH11 | ANGPTL | Breast | Healthy |
ANGPTL4 | CDH11 | ANGPTL4_CDH11 | ANGPTL | Breast | IDC |
ANGPTL4 | CDH11 | ANGPTL4_CDH11 | ANGPTL | Cervix | CC |
ANGPTL4 | CDH11 | ANGPTL4_CDH11 | ANGPTL | Endometrium | AEH |
ANGPTL4 | CDH11 | ANGPTL4_CDH11 | ANGPTL | Esophagus | ESCC |
ANGPTL4 | CDH11 | ANGPTL4_CDH11 | ANGPTL | HNSCC | OSCC |
ANGPTL4 | CDH11 | ANGPTL4_CDH11 | ANGPTL | HNSCC | Precancer |
ANGPTL4 | CDH11 | ANGPTL4_CDH11 | ANGPTL | Liver | HCC |
ANGPTL4 | CDH11 | ANGPTL4_CDH11 | ANGPTL | Prostate | Healthy |
ANGPTL4 | CDH11 | ANGPTL4_CDH11 | ANGPTL | Skin | ADJ |
ANGPTL4 | CDH11 | ANGPTL4_CDH11 | ANGPTL | Skin | Healthy |
ANGPTL4 | CDH11 | ANGPTL4_CDH11 | ANGPTL | THCA | Cancer |
ANGPTL4 | CDH11 | ANGPTL4_CDH11 | ANGPTL | THCA | Precancer |
ANGPTL4 | CDH11 | ANGPTL4_CDH11 | ANGPTL | THCA | PTC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDH11 | SNV | Missense_Mutation | rs747102834 | c.1063N>C | p.Asp355His | p.D355H | P55287 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-CN-6988-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CDH11 | SNV | Missense_Mutation | c.1063N>A | p.Asp355Asn | p.D355N | P55287 | protein_coding | deleterious(0.02) | probably_damaging(0.958) | TCGA-CR-7402-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD | |
CDH11 | SNV | Missense_Mutation | novel | c.1822G>T | p.Ala608Ser | p.A608S | P55287 | protein_coding | deleterious(0.01) | benign(0.034) | TCGA-CV-7101-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CDH11 | SNV | Missense_Mutation | rs777888128 | c.389N>T | p.Ala130Val | p.A130V | P55287 | protein_coding | tolerated(0.2) | possibly_damaging(0.852) | TCGA-CV-7414-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CDH11 | SNV | Missense_Mutation | rs868248780 | c.484N>A | p.Glu162Lys | p.E162K | P55287 | protein_coding | deleterious(0.02) | benign(0.036) | TCGA-CV-A45O-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CDH11 | SNV | Missense_Mutation | novel | c.1604N>A | p.Ile535Asn | p.I535N | P55287 | protein_coding | tolerated(0.25) | benign(0.028) | TCGA-CV-A6JZ-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CDH11 | SNV | Missense_Mutation | c.1894N>T | p.Val632Phe | p.V632F | P55287 | protein_coding | deleterious(0.01) | possibly_damaging(0.864) | TCGA-CV-A6K1-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
CDH11 | SNV | Missense_Mutation | rs199720066 | c.1108G>A | p.Val370Ile | p.V370I | P55287 | protein_coding | tolerated(0.25) | benign(0.099) | TCGA-F7-A50J-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
CDH11 | SNV | Missense_Mutation | novel | c.976N>C | p.Glu326Gln | p.E326Q | P55287 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-KU-A6H7-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CDH11 | SNV | Missense_Mutation | novel | c.1303N>A | p.Pro435Thr | p.P435T | P55287 | protein_coding | tolerated(0.22) | benign(0.062) | TCGA-QK-A8Z8-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1009 | CDH11 | CLINICALLY ACTIONABLE | RG6125 |
Page: 1 |